Toronto, Ontario--(Newsfile Corp. - June 12, 2021) - InterVivo Solutions (IVS) today announced availability of its first data set as part of the COPETM program. The program, launched in March, in collaboration with Mindset Pharma Inc. (CSE: MSET) aims to create the world's first preclinical behavioral and pharmacokinetics benchmark data for clinically relevant psychedelic drugs including Psilocybin, LSD, DMT, and 5-MeO-DMT amongst others.
Preliminary data released today focused on Psilocybin/Psilocin and demonstrate that the clinical exposure levels reported in humans correlate well to exposure and efficacy measures observed in mice - validating the predictive value of IVS's selected behavioural assays and animal models. Assuming these relationships apply to other reference psychedelics, this data should enable back translation of human clinical study data to IVS' behavioral models.
As part of the COPETM program, IVS is immediately making available its Bioanalytical Platform to its global client base, offering pre-developed and qualified LC-MS analytical protocols for a growing list of known psychedelics and related chemical compounds, including their active metabolites. Sponsors will be able to submit their in-life samples for analysis at InterVivo's bioanalytical lab, centrally located in the Greater Toronto Area. Lead investigators for the platform are Drs. Inés de Lannoy and Lilia Magomedova, who are overseeing its development and application to profiling the pharmacokinetics properties of the selected psychedelic molecules.
"On this day, 78 years ago, the first woman in history experienced the effects of LSD. Susi Ramstein was a laboratory assistant with Albert Hoffman at Sandoz labs in Basel where LSD was first synthesised. Despite the widespread interest in the therapeutic potential of psychedelics, there is relatively little preclinical data relating their efficacy/safety profiles to plasma and CNS exposures, and PK properties. Developing this knowledge base for psychedelics such as LSD and psilocybin, currently being evaluated in the clinic, will undoubtedly help the value assessment of newer psychedelics in development. This requires significant expertise in bioanalysis and pharmacokinetics and we are fortunate to have the expertise and leadership of Drs. de Lannoy and Magomedova to lead this research." Dr. Guy Higgins, Ph.D., Chief Scientific Officer of IVS and a Scientific Advisory Board member of Mindset, commented.
James Lanthier, CEO of Mindset commented: "We are developing the tools and metrics with which the industry will determine success and we're doing it faster than anyone thanks to the expertise at InterVivo. We're delighted with the progress and insights driving the efficiency of our drug development engine, and are eager to translate that knowledge into real value for the mental health crisis we aim to solve. Given the significance of the date, today we also acknowledge the contributions of our research partners and in particular the many Women of Science who have made so many unsung contributions to humanity's understanding of nature and medicine.
Detailed information on the COPETM Benchmark data set and the Bioanalytical Platform is being made available immediately to IVS sponsors, and plans for public dissemination are forthcoming. For enquiries and further information on the COPETM Program or Bioanalytical Platform please contact:
Director of Sales and Marketing